Journal
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Volume 13, Issue 8, Pages 1549-1556Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920112800784943
Keywords
Schizophrenia; Treatment; Glutamatergic system; NMDA receptor; Metabotropic Glutamate receptors; GABAergic interneurons
Ask authors/readers for more resources
For decades treatment of schizophrenia was restricted to drugs, which mainly target positive symptoms by interfering with the dopaminergic neurotransmission. Since a large body of experimental and clinical data implicate that schizophrenia may primarily be a consequence of an imbalance in the glutamatergic system, specifically the networks containing GABAergic interneurons (gamma-amino butyric acid), new drugs modulating glutamatergic neurotransmission are being developed. Targeting this dysfunction may follow different strategies, including application of direct or indirect NMDA (N-methyl-D-aspartate) receptor agonists or drugs modulating the function of metabotropic glutamate receptors. Meanwhile, the first substances have proven to be effective in animal models of schizophrenia and now enter the stage of clinical trials. The most promising data have been obtained in studies employing agonists of the metabotropic glutamate receptor. A choice of these substances is presented in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available